Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 19/20 | 0.70 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.57 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.57 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | ACACA | Q13085 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18097027 | 0.92 | ADORA2B (0.73) | ADORA2BADORA3ADORA2AADORA1ACACB | |
| SCHEMBL16637157 | 0.89 | ADORA2B (0.71) | ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL16643770 | 0.89 | ADORA2B (0.64) | ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL18097053 | 0.88 | ADORA2B (0.56) | ADORA2BADORA3ADORA2AADORA1ACACB | |
| SCHEMBL18097296 | 0.85 | ADORA2B (0.68) | ADORA2BADORA3ADORA2AADORA1ACACB | |
| SCHEMBL19923936 | 0.84 | ADORA2B (0.72) | ADORA2BACACBACACA | |
| SCHEMBL18096973 | 0.83 | ADORA2B (0.85) | ADORA2BACACBACACA | |
| SCHEMBL18097608 | 0.83 | ADORA2B (0.67) | ADORA2BADORA3ADORA2AADORA1ACACB | |
| SCHEMBL16637159 | 0.82 | ADORA2B (0.71) | ADORA2BADORA3ADORA2AADORA1 | |
| SCHEMBL16644071 | 0.81 | ADORA2B (0.60) | ADORA2BADORA3ADORA2AADORA1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-10-01 | — | — | US | disclosed |
| EP-3274352-B1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | Bayer Pharma AG (DE) | 2019-01-02 | — | — | EP | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2018-03-08 | — | — | US | disclosed |
| EP-3274352-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | Bayer Pharma Aktiengesellschaft (DE) | 2018-01-31 | — | — | EP | disclosed |
| WO-2016150901-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065981-A1 | HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTOR | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885ADORA3 3/4885ADORA2A 1/4885 |
| US-10428083-B2 | Heterocyclylmethyl-thienouracile as antagonists of the adenosine-A2B-receptor | ADORA2A, ADORA2B, ADORA3 | ADORA2B 2/4885ADORA3 3/4885ADORA2A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.